CONGRESS HIGHLIGHTS

Highlights in chronic myeloid leukaemia

BJH - volume 13, issue 5, september 2022

N. Granacher MD

SUMMARY

The treatment landscape of chronic myeloid leukaemia in chronic phase (CP-CML) is continuously changing. During the annual congress of the European Hematology Association (EHA 2022), new strategies to improve the management of CP-CML were presented. These novel strategies include new drugs, alternative treatment strategies to reduce toxicity without affecting efficacy, and new techniques to help identify the best patient subpopulation for treatment-free remission. The highlights of these new strategies are addressed in this article.

(BELG J HEMATOL 2022;13(5):183–7)

Read more

Highlights in AML and MDS

BJH - volume 13, issue 5, september 2022

D. Selleslag MD

SUMMARY

Very important changes in the field of AML and MDS have been presented at the meeting and have very recently been published in top journals. First of all, the new M-IPSS integrating molecular analysis in a prognostic score for MDS was discussed by Elli Papaemmanuil and published by Elsa Bernard in June 2022 in NEJM Evid.1 Secondly, the fifth edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms was published by J. Khoury.2 It introduced new entities in MDS and AML. Finally, the updated ELN (European Leukemia Net) guidelines for diagnosis and management of AML were published in Blood in July 2022 by Hartmut Döhner.3 The impact of these three 2022 publications on the management of MDS and AML cannot be overestimated. They are not part of this report but we strongly recommend reading these papers as a background. This report is focussing on the abstracts with potential clinical impact on the treatment of AML or MDS.

(BELG J HEMATOL 2022;13(5):190–9)

Read more

Highlights in Chronic Lymphocytic Leukaemia

BJH - volume 13, issue 5, september 2022

D. Bron MD, PhD

SUMMARY

Chronic lymphocytic leukaemia (CLL) is a rapidly progressing field in haemato-oncology. The EHA 2022 meeting again provided an update on major clinical trials, the prognostic impact of TP53 mutation in the era of BCL2inh, new insights into the role of marrow microenvironment in the course of the disease, new approaches to Richter’ syndrome and many new promising drugs. The oral presentations about this topic, with practical importance for the clinicians, are covered in this article.

(BELG J HEMATOL 2022;13(5):200–6)

Read more

Highlights in red blood cell disorders

BJH - volume 13, issue 5, september 2022

B. Gulbis MD, PhD

SUMMARY

Research in the field of haemoglobinopathies, and in particular for sickle cell disease, has enabled the implementation of new therapies, both modifying and curative. The congress was the opportunity to present the experience gained from their use in real life or in phase III trials; it has demonstrated their potential benefit while emphasising that careful monitoring of these new treatments remains necessary. The congress was also an opportunity to present new tools used in the field of haemoglobinopathies. They contribute to the assessment of the impact of new modifying therapies in sickle cell disease, i.e., oxygen gradient ektacytometry, or in the field of diagnosis using artificial intelligence, i.e., SCD silent cerebral infarct and liver iron overload.

(BELG J HEMATOL 2022;13(5):207–9)

Read more

Highlights in lymphoma

BJH - volume 13, issue 5, september 2022

S. Snauwaert MD, PhD

(BELG J HEMATOL 2022;13(5):210–3)

Read more

Best of EHA 2022

BJH - volume 13, issue 5, september 2022

M-C. Vekemans MD, PhD

SUMMARY

The 30th EHA meeting was held in Vienna in June 2022, an opportunity to meet again with colleagues from all over the world after two years of restrictions due to the COVID-19 pandemic. We selected ten abstracts featuring clinical advances and novel treatment approaches across hematologic diseases, abstracts that will probably change our daily practice in the near future.

(BELG J HEMATOL 2022;13(5):214–8)

Read more

Highlights in multiple myeloma

BJH - volume 13, issue 5, september 2022

J. Blokken PhD, PharmD, T. Feys MBA, MSc

SUMMARY

During the past European Hematology Association’s annual congress (EHA 2022), four oral sessions were devoted to clinical trials and recent advances in myeloma. These sessions covered newly diagnosed multiple myeloma (MM), antibody-based therapy in relapsed/refractory (RR) MM, BCMA-directed treatment in RRMM and biology and translational research. Below, we summarise the highlights from some of the studies that were presented in each of these sessions.

(BELG J HEMATOL 2022;13(5):219–23)

Read more
X